These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34076257)

  • 1. Group sequential testing for cluster randomized trials with time-to-event endpoint.
    Li J; Jung SH
    Biometrics; 2022 Dec; 78(4):1353-1364. PubMed ID: 34076257
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sample size calculation for cluster randomization trials with a time-to-event endpoint.
    Li J; Jung SH
    Stat Med; 2020 Nov; 39(25):3608-3623. PubMed ID: 33463748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and analysis of cluster randomized trials with time-to-event outcomes under the additive hazards mixed model.
    Blaha O; Esserman D; Li F
    Stat Med; 2022 Oct; 41(24):4860-4885. PubMed ID: 35908796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sample size requirements for testing treatment effect heterogeneity in cluster randomized trials with binary outcomes.
    Maleyeff L; Wang R; Haneuse S; Li F
    Stat Med; 2023 Nov; 42(27):5054-5083. PubMed ID: 37974475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sample size calculation for clustered survival data under subunit randomization.
    Li J; Jung SH
    Lifetime Data Anal; 2022 Jan; 28(1):40-67. PubMed ID: 34716530
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Power analysis for cluster randomized trials with multiple binary co-primary endpoints.
    Li D; Cao J; Zhang S
    Biometrics; 2020 Dec; 76(4):1064-1074. PubMed ID: 31872435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Power and sample size calculations for cluster randomized trials with binary outcomes when intracluster correlation coefficients vary by treatment arm.
    Kennedy-Shaffer L; Hughes MD
    Clin Trials; 2022 Feb; 19(1):42-51. PubMed ID: 34879711
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Accounting for expected attrition in the planning of cluster randomized trials for assessing treatment effect heterogeneity.
    Tong J; Li F; Harhay MO; Tong G
    BMC Med Res Methodol; 2023 Apr; 23(1):85. PubMed ID: 37024809
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Group sequential methods for cluster randomization trials with binary outcomes.
    Zou GY; Donner A; Klar N
    Clin Trials; 2005; 2(6):479-87. PubMed ID: 16422308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Information growth for sequential monitoring of clinical trials with a stepped wedge cluster randomized design and unknown intracluster correlation.
    Brown SP; Shoben AB
    Clin Trials; 2020 Apr; 17(2):176-183. PubMed ID: 32026713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size estimation for stratified individual and cluster randomized trials with binary outcomes.
    Kennedy-Shaffer L; Hughes MD
    Stat Med; 2020 May; 39(10):1489-1513. PubMed ID: 32003492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methodological review showed that time-to-event outcomes are often inadequately handled in cluster randomized trials.
    Caille A; Tavernier E; Taljaard M; Desmée S
    J Clin Epidemiol; 2021 Jun; 134():125-137. PubMed ID: 33581243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sample size estimation for stratified cluster randomization trial with survival endpoint.
    Ni S; Zhong Z; Zhao Y; Chen F; Wu J; Yu H; Bai J
    Stat Methods Med Res; 2024 May; 33(5):838-857. PubMed ID: 38549457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size calculation for weighted rank tests comparing survival distributions under cluster randomization: a simulation method.
    Jung SH
    J Biopharm Stat; 2007; 17(5):839-49. PubMed ID: 17885869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the estimation of intracluster correlation for time-to-event outcomes in cluster randomized trials.
    Kalia S; Klar N; Donner A
    Stat Med; 2016 Dec; 35(30):5551-5560. PubMed ID: 27790737
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sample size and power considerations for cluster randomized trials with count outcomes subject to right truncation.
    Li F; Tong G
    Biom J; 2021 Jun; 63(5):1052-1071. PubMed ID: 33751620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stepped wedge designs could reduce the required sample size in cluster randomized trials.
    Woertman W; de Hoop E; Moerbeek M; Zuidema SU; Gerritsen DL; Teerenstra S
    J Clin Epidemiol; 2013 Jul; 66(7):752-8. PubMed ID: 23523551
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reporting and methodological quality of sample size calculations in cluster randomized trials could be improved: a review.
    Rutterford C; Taljaard M; Dixon S; Copas A; Eldridge S
    J Clin Epidemiol; 2015 Jun; 68(6):716-23. PubMed ID: 25523375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Group Sequential Design for Randomized Phase III Trials under the Weibull Model.
    Wu J; Xiong X
    J Biopharm Stat; 2015; 25(6):1190-205. PubMed ID: 25322440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Power analysis for cluster randomized trials with continuous coprimary endpoints.
    Yang S; Moerbeek M; Taljaard M; Li F
    Biometrics; 2023 Jun; 79(2):1293-1305. PubMed ID: 35531926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.